Optiscan and Mayo Clinic Reach Two-Year Milestone in Robotic Imaging Development

Completion of Engineering Milestones Marks Progress

Optiscan Imaging Ltd (ASX:OIL) and the Mayo Clinic have marked the two-year anniversary of their Know-How Agreement, culminating in the completion of all major engineering milestones for a digital endomicroscopic imaging system tailored for robotic surgery. This partnership has focused on adapting Optiscan’s high-resolution imaging technology to function seamlessly within robotic surgical platforms, aiming to enhance intraoperative precision and decision-making.

The collaboration has seen progress from concept development through to prototype creation and integration testing, with Mayo Clinic surgeons actively involved in assessing how the technology fits into existing robotic-assisted breast surgery workflows. This hands-on clinical input has ensured that the imaging system aligns with real-world surgical needs, including compatibility with hardware and software pathways of robotic platforms.

Strategic Extension Supports Next Phase Planning

To facilitate further strategic, clinical, and commercial planning, the Agreement has been extended by three months to 12 August 2026. This extension positions both parties to prepare for anticipated preclinical testing and subsequent clinical protocols, which will proceed outside the current Agreement and remain subject to regulatory and ethical approvals.

Optiscan’s CEO, Dr Camile Farah, highlighted the significance of this milestone, noting the potential for robotic tools to hold the imaging device, potentially offering greater stability and precision at the microscopic level than manual operation. The collaboration is designed to enable live cellular-level visualization during robotic procedures, supporting more informed surgical decisions and potentially reducing the need for additional interventions.

Commercial and Regulatory Implications

The partnership with Mayo Clinic, a globally respected healthcare institution, reinforces Optiscan’s US expansion strategy and bolsters its positioning within the rapidly growing robotic surgery market. The US accounts for over half of the global surgical robotics market, valued at approximately USD $7 to $7.5 billion and expanding at an annual rate of 11% to 13.5%.

Progress under the Agreement has demonstrated the feasibility of integrating Optiscan’s imaging streams into robotic visualization systems using Picture-in-Picture protocols, maintaining compatibility with existing surgeon interfaces. These developments pave the way for further preclinical and clinical testing focused initially on robotic-assisted breast surgery.

Clinical Collaboration Drives Innovation

Dr Mara Piltin, surgical lead at Mayo Clinic on the project, emphasised the strong combination of clinical insight and technical development achieved so far. The ongoing evaluation of real-time microscopic imaging integration into robotic surgery workflows aims to support more precise intraoperative decision-making, potentially transforming surgical approaches.

While the current phase concludes the engineering development under the Know-How Agreement, the next steps will focus on clinical validation and regulatory clearances, which remain contingent on standard ethics and clinical study approvals.